Should You Buy Crescent Capital BDC Inc (CCAP) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Buy
Latest Price
14.350
1 Day change
1.20%
52 Week Range
19.650
Analysis Updated At
2026/01/28
BUY now for a beginner long-term investor. CCAP is trading around $14.43 near key support ($14.28) with improving short-term momentum (MACD turning up) and broadly bullish options positioning (low put/call open-interest ratio). While the latest quarter (2025/Q3) showed meaningful YoY declines and credit-mark pressure, Wall Street still largely maintains Buy/Outperform ratings and the stock price appears to be discounting many of the credit concerns already. With your preference for long-term holding and no desire to wait for a perfect entry, the current level is a reasonable entry point.
Technical Analysis
Trend/momentum: Mild bullish turn. MACD histogram is positive (0.00373) and expanding, suggesting momentum is improving. RSI(6) ~56 is neutral-to-slightly bullish (not overbought). Moving averages are converging, implying the prior downtrend/sideways action may be stabilizing.
Levels: Current price $14.43 is just below the pivot ($14.567). Near-term support sits at S1 $14.282 (then S2 $14.107). Resistance levels to clear are R1 $14.852 and R2 $15.027. Practical read: risk/reward is acceptable near support; a move above ~$14.57–$14.85 would confirm more upside momentum.
Pattern-based near-term bias (provided): modestly negative over a month (-1.23% expected) but relatively flat over a week (+0.17%), consistent with a stabilizing/sideways setup rather than a strong downtrend.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Sentiment: Bullish-to-neutral. Put/call open interest ratio of 0.38 suggests more call positioning than puts (generally constructive).
Activity/liquidity: Very light volume (only 2 contracts today; 0 puts), so the volume-based signal is weak despite the bullish skew.
Volatility: 30D IV ~38.93 vs historical vol ~30.11 (IV elevated). IV percentile ~67.6 indicates options are pricing above-average uncertainty relative to the past year, consistent with investors still factoring credit/portfolio risk.
Technical Summary
Sell
10
Buy
0
Positive Catalysts
on 2026-02-23 (After Hours). A cleaner credit-mark/portfolio update could re-rate the stock.
Neutral/Negative Catalysts
implies the market still prices meaningful uncertainty.
Financial Performance
Latest reported quarter: 2025/Q3.
Growth trend: materially weaker YoY.
- Revenue: 31.525M, down 27.29% YoY
- Net Income: 7.102M, down 53.48% YoY
- EPS: 0.19, down 53.66% YoY
- Gross Margin: 86.9%, down 0.31% YoY (roughly stable margin, but earnings power declined sharply)
Takeaway: The core concern is earnings/credit pressure rather than margin collapse; the company needs stabilization in portfolio performance/credit marks for a durable multi-quarter rebound.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend (Nov 2025): Broad price-target cuts across the board after Q3 results, but ratings largely held.
- Oppenheimer: PT cut to $19 from $20; kept Outperform
- Ladenburg: PT cut to $16 from $16.50; kept Buy
- Wells Fargo: PT cut to $14 from $15; kept Equal Weight (most cautious)
- Keefe Bruyette: PT cut to $15.50 from $17; kept Outperform
- Clear Street: PT cut to $15.50 from $16.50; kept Buy
Wall Street pros: perceived discount already reflects risk; dividend coverage cited; potential upside if credit marks stabilize and/or repurchases increase.
Wall Street cons: ongoing credit marks/portfolio stress; management capital allocation (limited repurchases) questioned; targets reduced signals tempered expectations.
Wall Street analysts forecast CCAP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CCAP is 16 USD with a low forecast of 14 USD and a high forecast of 19 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast CCAP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CCAP is 16 USD with a low forecast of 14 USD and a high forecast of 19 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 14.180
Low
14
Averages
16
High
19
Current: 14.180
Low
14
Averages
16
High
19
Oppenheimer
Oppenheimer
Outperform
downgrade
$20 -> $19
AI Analysis
2025-11-14
Reason
Oppenheimer
Oppenheimer
Price Target
$20 -> $19
AI Analysis
2025-11-14
downgrade
Outperform
Reason
Oppenheimer lowered the firm's price target on Crescent Capital BDC to $19 from $20 and keeps an Outperform rating on the shares following quarterly results. The firm says its estimate changes reflect Q3 actuals and updated guidance.
Ladenburg
Buy -> Buy
downgrade
$16
2025-11-14
Reason
Ladenburg
Price Target
$16
2025-11-14
downgrade
Buy -> Buy
Reason
Ladenburg lowered the firm's price target on Crescent Capital BDC to $16 from $16.50 and keeps a Buy rating on the shares following the Q3 report.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CCAP
